Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$104.8 million.

  • Intellia Therapeutics' Net Income towards Common Stockholders rose 2102.18% to -$104.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.4 million, marking a year-over-year increase of 874.79%. This contributed to the annual value of -$486.5 million for FY2024, which is 451.1% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Net Income towards Common Stockholders stood at -$104.8 million, which was up 2102.18% from -$102.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Net Income towards Common Stockholders registered a high of -$46.2 million during Q1 2021, and its lowest value of -$143.7 million during Q1 2022.
  • Its 5-year average for Net Income towards Common Stockholders is -$104.6 million, with a median of -$104.7 million in 2022.
  • Per our database at Business Quant, Intellia Therapeutics' Net Income towards Common Stockholders crashed by 21101.83% in 2022 and then skyrocketed by 3042.88% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$79.9 million in 2021, then plummeted by 31.06% to -$104.7 million in 2022, then dropped by 21.67% to -$127.4 million in 2023, then rose by 1.27% to -$125.8 million in 2024, then rose by 16.73% to -$104.8 million in 2025.
  • Its last three reported values are -$104.8 million in Q3 2025, -$102.6 million for Q2 2025, and -$112.2 million during Q1 2025.